# AHSG

## Overview
The AHSG gene encodes the protein alpha 2-HS glycoprotein, commonly referred to as fetuin-A, which is a multifunctional plasma glycoprotein primarily synthesized in the liver. As a member of the cystatin superfamily, fetuin-A is involved in various physiological processes, including the inhibition of ectopic calcification and modulation of insulin signaling. The protein's structure comprises two cystatin-like domains that contribute to its role as a calcification inhibitor by forming complexes with calcium and phosphate ions. Fetuin-A also plays a significant role in bone metabolism and inflammatory response regulation. The gene's expression is regulated by interactions with transcription factors and is subject to modulation by hormones such as estrogen. Variations in the AHSG gene have been linked to several clinical conditions, including cardiovascular diseases and metabolic disorders, highlighting its importance in human health (Heiss2003Structural; Goustin2011The; Lavebratt2005AHSG).

## Structure
The human alpha 2-HS glycoprotein (AHSG), also known as fetuin-A, is a plasma protein encoded by the AHSG gene located on chromosome 3. The protein is composed of two polypeptide chains, the A and B chains, which are linked by a disulfide bond. These chains are encoded by a single mRNA transcript that includes a unique 40-amino-acid connecting sequence cleaved post-translationally to produce the mature protein (Lee1987Human).

AHSG contains two cystatin-like domains, with the amino-terminal domain D1 playing a crucial role in inhibiting basic calcium phosphate precipitation. This domain features a dense array of acidic residues on an extended β-sheet, which is essential for its function as a calcification inhibitor (Heiss2003Structural). The protein undergoes post-translational modifications, including glycosylation and phosphorylation, which influence its functional properties (Heiss2003Structural).

AHSG is known to form soluble, colloidal complexes with calcium and phosphate, termed calciprotein particles, which prevent unwanted calcification by delaying the growth of insoluble crystals (Heiss2003Structural). The protein exists in multiple isoforms due to alternative splicing, contributing to its diverse functional roles.

## Function
The AHSG gene encodes the protein fetuin-A, which plays a significant role in various molecular processes in healthy human cells. Fetuin-A is primarily synthesized in the liver and acts as a natural inhibitor of insulin receptor tyrosine kinase activity. This inhibition is crucial for regulating insulin signaling and glucose homeostasis, as fetuin-A reduces the Vmax of the insulin-stimulated insulin receptor tyrosine kinase reaction and increases the half-saturating substrate concentration for ATP and other substrates (Goustin2011The; Mathews2002Improved).

Fetuin-A is also involved in bone metabolism, where it inhibits the precipitation of calcium salts, a key process in bone mineralization. This function is attributed to its high affinity for hydroxyapatite, a major component of bone, thereby preventing excessive calcium salt precipitation and modulating bone mineralization (Schinke1996The).

In addition to its role in insulin signaling and bone metabolism, fetuin-A is active in the extracellular matrix and circulatory system, where it modulates inflammatory responses and ectopic calcification. Its presence in the bloodstream and interaction with the insulin receptor suggest a broader role in metabolic regulation and energy storage (Goustin2011The; Dabrowska2015FetuinA).

## Clinical Significance
Mutations and alterations in the AHSG gene, also known as alpha 2-HS glycoprotein or fetuin-A, have been associated with several clinical conditions. A homozygous missense mutation in the AHSG gene has been linked to alopecia and mental retardation (APMR) syndrome, a rare autosomal recessive disorder characterized by hair loss and intellectual disability. This mutation, identified as p.Arg317His, affects a phosphorylation motif, potentially disrupting protein processing and post-translational modifications, which are crucial for its function (Reza2017Association).

In the context of cardiovascular diseases, polymorphisms in the AHSG gene have been associated with variations in fetuin-A plasma levels, influencing the risk of myocardial infarction and ischemic stroke. The SNP rs4917, in particular, has been linked to increased cardiovascular risk, with its effects mediated through altered fetuin-A levels (Fisher2009Association).

AHSG gene variants have also been implicated in metabolic conditions. Certain polymorphisms are associated with leanness and obesity, potentially affecting insulin sensitivity and resistance to diet-induced obesity (Lavebratt2005AHSG). Additionally, AHSG deficiency in mice leads to severe ectopic calcification, suggesting its role as a systemic inhibitor of calcification (Schäfer2003The).

## Interactions
Alpha 2-HS glycoprotein (AHSG), also known as fetuin-A, participates in several significant protein interactions. It interacts with transcription factors such as C/EBP (CCAAT/enhancer-binding protein) and HNF-3 (hepatocyte nuclear factor 3), which bind to the promoter region of the AHSG gene to regulate its expression. These interactions are crucial for the dexamethasone-induced up-regulation of AHSG gene expression (Wöltje2006CCAAT).

AHSG also interacts with estrogen receptor alpha (ERα) and activator protein-1 (AP-1) components, c-Jun and c-Fos, at the AHSG promoter. This interaction is enhanced by estrogen, leading to increased transcriptional activation of the AHSG gene (Qiu2014Estrogen).

In terms of cytokine interactions, AHSG acts as a cytokine antagonist by binding to transforming growth factor-beta (TGF-β) and bone morphogenetic proteins (BMPs), such as BMP-2, BMP-4, and BMP-6. This binding suggests that AHSG can modulate cytokine activity and potentially act as a reservoir for cytokines during bone remodeling (Demetriou1996Fetuinα2HS).

AHSG is also a substrate for the serine protease matriptase-2, which cleaves AHSG, affecting its role in iron homeostasis by modulating hepcidin expression (Stirnberg2014Cell).


## References


[1. (Heiss2003Structural) Alexander Heiss, Alexander DuChesne, Bernd Denecke, Joachim Grötzinger, Kazuhiko Yamamoto, Thomas Renné, and Willi Jahnen-Dechent. Structural basis of calcification inhibition by α2-hs glycoprotein/fetuin-a. Journal of Biological Chemistry, 278(15):13333–13341, April 2003. URL: http://dx.doi.org/10.1074/JBC.M210868200, doi:10.1074/jbc.m210868200. This article has 677 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.M210868200)

[2. (Lee1987Human) C C Lee, B H Bowman, and F M Yang. Human alpha 2-hs-glycoprotein: the a and b chains with a connecting sequence are encoded by a single mrna transcript. Proceedings of the National Academy of Sciences, 84(13):4403–4407, July 1987. URL: http://dx.doi.org/10.1073/pnas.84.13.4403, doi:10.1073/pnas.84.13.4403. This article has 72 citations.](https://doi.org/10.1073/pnas.84.13.4403)

[3. (Schinke1996The) Thorsten Schinke, Christiane Amendt, Andreas Trindl, Oliver Pöschke, Werner Müller-Esterl, and Willi Jahnen-Dechent. The serum protein α2-hs glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. Journal of Biological Chemistry, 271(34):20789–20796, August 1996. URL: http://dx.doi.org/10.1074/jbc.271.34.20789, doi:10.1074/jbc.271.34.20789. This article has 282 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.271.34.20789)

[4. (Mathews2002Improved) Suresh T. Mathews, Gurmant P. Singh, Mollie Ranalletta, Vivian J. Cintron, Xiaoling Qiang, Anton Scott Goustin, Kai-Lin Catherine Jen, Maureen J. Charron, Willi Jahnen-Dechent, and George Grunberger. Improved insulin sensitivity and resistance to weight gain in mice null for the ahsg gene. Diabetes, 51(8):2450–2458, August 2002. URL: http://dx.doi.org/10.2337/diabetes.51.8.2450, doi:10.2337/diabetes.51.8.2450. This article has 273 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/diabetes.51.8.2450)

[5. (Reza2017Association) M. Reza Sailani, Fereshteh Jahanbani, Jafar Nasiri, Mahdiyeh Behnam, Mansoor Salehi, Maryam Sedghi, Majid Hoseinzadeh, Shinichi Takahashi, Amin Zia, Joshua Gruber, Janet Linnea Lynch, Daniel Lam, Juliane Winkelmann, Semira Amirkiai, Baoxu Pang, Shannon Rego, Safoura Mazroui, Jonathan A. Bernstein, and Michael P. Snyder. Association of ahsg with alopecia and mental retardation (apmr) syndrome. Human Genetics, 136(3):287–296, January 2017. URL: http://dx.doi.org/10.1007/s00439-016-1756-5, doi:10.1007/s00439-016-1756-5. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00439-016-1756-5)

[6. (Schäfer2003The) Cora Schäfer, Alexander Heiss, Anke Schwarz, Ralf Westenfeld, Markus Ketteler, Jürgen Floege, Werner Müller-Esterl, Thorsten Schinke, and Willi Jahnen-Dechent. The serum protein α2–heremans-schmid glycoprotein/fetuin-a is a systemically acting inhibitor of ectopic calcification. Journal of Clinical Investigation, 112(3):357–366, August 2003. URL: http://dx.doi.org/10.1172/jci17202, doi:10.1172/jci17202. This article has 667 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci17202)

[7. (Wöltje2006CCAAT) Michael Wöltje, Beate Tschöke, Verena von Bülow, Ralf Westenfeld, Bernd Denecke, Steffen Gräber, and Willi Jahnen-Dechent. Ccaat enhancer binding protein β and hepatocyte nuclear factor 3β are necessary and sufficient to mediate dexamethasone-induced up-regulation of alpha2hs-glycoprotein/fetuin-a gene expression. Journal of Molecular Endocrinology, 36(2):261–277, April 2006. URL: http://dx.doi.org/10.1677/jme.1.02001, doi:10.1677/jme.1.02001. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1677/jme.1.02001)

[8. (Dabrowska2015FetuinA) Anna Maria Dabrowska, Jerzy Stanislaw Tarach, Beata Wojtysiak-Duma, and Dariusz Duma. Fetuin-a (ahsg) and its usefulness in clinical practice. review of the literature. Biomedical Papers, 159(3):352–359, September 2015. URL: http://dx.doi.org/10.5507/bp.2015.018, doi:10.5507/bp.2015.018. This article has 64 citations.](https://doi.org/10.5507/bp.2015.018)

[9. (Stirnberg2014Cell) Marit Stirnberg, Eva Maurer, Katharina Arenz, Anne Babler, Willi Jahnen-Dechent, and Michael Gütschow. Cell surface serine protease matriptase-2 suppresses fetuin-a/ahsg-mediated induction of hepcidin. Biological Chemistry, 396(1):81–93, September 2014. URL: http://dx.doi.org/10.1515/hsz-2014-0120, doi:10.1515/hsz-2014-0120. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/hsz-2014-0120)

[10. (Lavebratt2005AHSG) Catharina Lavebratt, Sofia Wahlqvist, Louise Nordfors, Johan Hoffstedt, and Peter Arner. Ahsg gene variant is associated with leanness among swedish men. Human Genetics, 117(1):54–60, April 2005. URL: http://dx.doi.org/10.1007/s00439-005-1286-z, doi:10.1007/s00439-005-1286-z. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00439-005-1286-z)

[11. (Qiu2014Estrogen) C. Qiu, X. Liu, J. Wang, Y. Zhao, and Q. Fu. Estrogen increases the transcription of human α2-heremans-schmid-glycoprotein by an interplay of estrogen receptor α and activator protein-1. Osteoporosis International, 25(4):1357–1367, February 2014. URL: http://dx.doi.org/10.1007/s00198-013-2613-1, doi:10.1007/s00198-013-2613-1. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00198-013-2613-1)

[12. (Fisher2009Association) Eva Fisher, Norbert Stefan, Kathrin Saar, Dagmar Drogan, Matthias B. Schulze, Andreas Fritsche, Hans-Georg Joost, Hans-Ulrich Häring, Norbert Hubner, Heiner Boeing, and Cornelia Weikert. Association of ahsg gene polymorphisms with fetuin-a plasma levels and cardiovascular diseases in the epic-potsdam study. Circulation: Cardiovascular Genetics, 2(6):607–613, December 2009. URL: http://dx.doi.org/10.1161/CIRCGENETICS.109.870410, doi:10.1161/circgenetics.109.870410. This article has 126 citations and is from a peer-reviewed journal.](https://doi.org/10.1161/CIRCGENETICS.109.870410)

[13. (Goustin2011The) Anton-Scott Goustin and Abdul B. Abou-Samra. The “thrifty” gene encoding ahsg/fetuin-a meets the insulin receptor: insights into the mechanism of insulin resistance. Cellular Signalling, 23(6):980–990, June 2011. URL: http://dx.doi.org/10.1016/j.cellsig.2010.11.003, doi:10.1016/j.cellsig.2010.11.003. This article has 119 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2010.11.003)

[14. (Demetriou1996Fetuinα2HS) Michael Demetriou, Christoph Binkert, Balram Sukhu, Howard C. Tenenbaum, and James W. Dennis. Fetuin/α2-hs glycoprotein is a transforming growth factor-β type ii receptor mimic and cytokine antagonist. Journal of Biological Chemistry, 271(22):12755–12761, May 1996. URL: http://dx.doi.org/10.1074/jbc.271.22.12755, doi:10.1074/jbc.271.22.12755. This article has 203 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.271.22.12755)